Overview

Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of ociperlimab with tislelizumab and chemotherapy compared with treatment with tislelizumab and chemotherapy in participants with metastatic non-small cell lung cancer (NSCLC)
Phase:
Phase 2
Details
Lead Sponsor:
BeiGene